High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study

Journal of Clinical Oncology

Volumn 13, Issue 12, 1995, Pages 2916-2923

  Shipp, Margaret A ^a   Neuberg, Donna ^b   Janicek, Milos ^b   Canellos, George P ^b   Shulman, Lawrence N ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VOMITING;

EID: 0028793717     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.12.2916     Document Type: Article

References (25)

1. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165-1173, 1994
2. Skarin AT, Canellos GP, Rosenthal DS, et al: Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (MBACOD). J Clin Oncol 1:91-97, 1983
3. Shipp MA, Yeap BY, Harrington DP. et al: The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8:84-93, 1990
4. Klimo P. Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
5. Longo DL, DeVita VT Jr, Duffey PL, et al: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991
6. Boyd DB, Coleman M, Parish SW, et al: COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 6:425-433, 1988
7. Coiffier B, Gisselbrecht C, Herbrecht R, et al: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
8. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 4:651-656, 1993
9. Gordon LI, Harrington D, Anderson J. et al: Comparison of second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349, 1992
10. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
11. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757-765, 1986
12. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990
13. Collins C, Mortimer J, Livingston RB: High-dose cyclophosphamide in the treatment of refractory lymphoma and solid tumor malignancies. Cancer 63:228-232, 1989
14. Takvorian T, Canellos GP, Ritz J, et al: Prolonged disease free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 316:1499-1505, 1987
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
17. Kumar L: Epipodophyllotoxins and secondary leukaemia. Lancet 342:819-820, 1993
18. Gill Super HJ, McCabe NR, Thirman MJ, et al: Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82:3705-3711, 1993
19. DeCillis A, Anderson S, Wickerham DL, et al: Acute myeloid leukemia (AML) in NSABP B-25. Proc Am Soc Clin Oncol 14:98, 1995 (abstr 92)
20. Greenbaum BH: Transfusion-associated graft-versus-host disease: Historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 9:1889-1902, 1991
21. Gianni AM, Bregni M, Siena S, et al: 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proc Am Soc Clin Oncol 13:373, 1994 (abstr 1263)
22. Verdonck LF, Van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995
23. Gherlinzoni F, Martelli M, Mazza P, et al: Autologous bone marrow transplantation (ABMT) vs DHAP in aggressive non-Hodgkin's lymphomas (NHL) partially responding to first-line chemotherapy. Blood 84:234a, 1994 (abstr 922)
24. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 12:2543-2551, 1994
25. Janicek M, Kaplan W, Neuberg D, et al: Early restaging gallium scans identify durable responses to induction therapy in high risk patients with aggressive non-Hodgkin's lymphoma (NHL). Blood 84:233a, 1994 (abstr 916)